Aggregation of vascular risk factors and risk of incident Alzheimer disease

Neurology

Volumn 65, Issue 4, 2005, Pages 545-551

  Luchsinger, J A ^a,b,c,d   Reitz, C ^a   Honig, L S ^a,b,c   Tang, M X ^a,b   Shea, Steven ^a,c   Mayeux, R ^a,b,c  

^a Columbia University ^*  (United States)

^b Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^c NONE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALZHEIMER DISEASE; ARTICLE; CARDIOVASCULAR RISK; DEMENTIA; DIABETES MELLITUS; DISEASE PREDISPOSITION; FEMALE; HEART DISEASE; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING;

EID: 23844522541     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000172914.08967.dc     Document Type: Article

References (92)

1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337-1342.
2. Luchsinger J, Mayeux R. Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep 2004;6:261-266.
3. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-524.
4. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002;287:1003-1010.
5. Morgan JM, Capuzzi DM. Hypercholesterolemia. The NCEP Adult Treatment Panel III Guidelines. Geriatrics 2003;58:33-38.
6. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999;53:1937-1942.
7. Leibson CL, Rocca WA, Hanson VA, et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 1997;145:301-308.
8. Peila R, Rodriguez BL, Laurer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002;51:1256-1262.
9. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000;356:1627-1631.
10. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-1145.
11. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997;28:316-321.
12. Ott A, Slooter AJ, Hofman A, et al. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 1998;351:1840-1843.
13. Merchant C, Tang M-X, Albert S, Manly J, Stern Y, Mayeux R. The influence of smoking on the risk of Alzheimer's disease. Neurology 1999;52:1408.
14. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346: 476-483.
15. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 2003;163:1524-1528.
16. Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 2000;21:153-160.
17. Reaven GM, Laws A. Insulin resistance: the metabolic syndrome X. Totowa, NJ: Humana Press, 1999.
18. Szklo M, Nieto F. Overadjustment. Epidemiology: beyond the basics. Gaithersburg, MD: Aspen, 2000;331-333.
19. Luchsinger JA, Tang M-X, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer's disease. Neurology 2004;63:1187-1192.
20. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001;154:635-641.
21. Merchant C, Tang MX, Albert S, Manly J, Stern Y, Mayeux R. The influence of smoking on the risk of Alzheimer's disease. Neurology 1999;52:1408-1412.
22. Posner HB, Tang MX, Luchsinger J, Lantigua R, Stern Y, Mayeux R. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 2002;58:1175-1181.
23. Reitz C, Tang M-X, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 2004;61:705-714.
24. Moroney JT, Tang MX, Berglund L, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 1999;282:254-260.
25. Luchsinger JA, Tang M-X, Shea S, Miller J, Green R, Mayeux R. Plasma homocysteine levels and risk of Alzheimer disease. Neurology 2004;62:1972-1976.
26. Honig LS, Tang MX, Albert S, et al. Stroke and the risk of Alzheimer disease. Arch Neurol 2003;60:1707-1712.
27. Tang MX, Stern Y, Marder K, et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 1998;279:751-755.
28. Stern Y, Andrews H, Pittman J, et al. Diagnosis of dementia in a heterogeneous population. Development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol 1992;49:453-460.
29. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention: detection, evaluation, and treatment of high blood pressure: the JNC 7 report [erratum appears in JAMA 2003;290:197], JAMA 2003;289:2560-2572.
30. Lopes-Virella MF, Stone P, Ellis S, Colwell JA. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem 1977;23:882-884.
31. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
32. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31: 545-548.
33. Mayeux R, Ottman R, Maestre G, et al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 1995;45:555-557.
34. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 1997;275:630-631.
35. Hofman A, Ott A, Breteler MM, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997;349:151-154.
36. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull WHO 1976;54:541-553.
37. Bureau of the Census 1990 census of populations and housing: summary tape file 1, technical documentation (computer diskette). Washington, DC: Bureau of the Census, 1991.
38. Luchsinger JA Diabetes. In: Aguirre-Molina M, Molina CW, Zambrana R, eds. Health issues in the Latino community. San Francisco: Jossey-Bass, 2001;277-300.
39. Tang MX, Cross P, Andrews H, et al. Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology 2001;56:49-56.
40. American Psychiatric Association, Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Press, 1997.
41. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
42. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944.
43. Cox DR, Oakes D. Analysis of survival data. London: Chapman & Hall, 1984.
44. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 1997;145:72-80.
45. Ryglewicz D, Rodo M, Kunicki PK, et al. Plasma antioxidant activity and vascular dementia. J Neurol Sci 2002;203/204:195-197.
46. Tatemiehi TK, Desmond DW, Mayeux R, et al. Dementia after stroke: baseline frequency, risks, and clinical features in a hospitalized cohort. Neurology 1992;42:1185-1193.
47. Tatemiehi TK, Paik M, Bagiella E, et al. Risk of dementia after stroke in a hospitalized cohort: results of a longitudinal study. Neurology 1994;44:1885-1891.
48. O'Leary DH, Polak JF, Kronmal RA, et al. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke 1992;23: 1752-1760.
49. Mast H, Thompson JL, Lee SH, Mohr JP, Sacco RL. Hypertension and diabetes mellitus as determinants of multiple lacunar infarcts. Stroke 1995;26:30-33.
50. Elmore EM, Mosquera A, Weinberger J. The prevalence of asymptomatic intracranial large-vessel occlusive disease: the role of diabetes. J Neuroimag 2003;13:224-227.
51. Polidori MC, Marvardi M, Cherubini A, Senin U, Mecocci P. Heart disease and vascular risk factors in the cognitively impaired elderly: implications for Alzheimer's dementia. Aging (Milano) 2001;13:231-239.
52. Lis CG, Gaviria M. Vascular dementia, hypertension, and the brain. Neurol Res 1997;19:471-480.
53. Petty LA, Parker JR, Parker JC, Jr. Hypertension and vascular dementia. Ann Clin Lab Sci 1992;22:34-39.
54. Suryadevara V, Storey SG, Aronow WS, Ahn C. Association of abnormal serum lipids in elderly persons with atherosclerotic vascular disease and dementia, atherosclerotic vascular disease without dementia, dementia without atherosclerotic vascular disease, and no dementia or atherosclerotic vascular disease. J Gerontol A Biol Sci Med Sci 2003;58: M859-M861.
55. Nitsch RM, From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease, Neurodegeneration 1996;5:477-482.
56. Sparks DL, Martin TA, Gross DR, Hunsaker JC, 3rd. Link between heart disease, cholesterol, and Alzheimer's disease: a review. Microsci Res Technol 2000;50:287-290.
57. Petrovitch H, White LR, Izmirilian G, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia Aging Study. Neurobiol Aging 2000;21:57-62.
58. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215-1222.
59. Skoog I. The relationship between blood pressure and dementia: a review. Biomed Pharmacother 1997;51:367-375.
60. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol 1986;19:253-262.
61. de la Monte SM. Quantitation of cerebral atrophy in preclinical and end-stage Alzheimer's disease. Ann Neurol 1989;25:450-459.
62. Nag S. Cerebral changes in chronic hypertension: combined permeability and immunohistochemical studies. Acta Neuropathol (Berl) 1984;62: 178-184.
63. Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol (Berl) 1982;57:239-242.
64. Licandro A, Ferla S, Tavolato B. Alzheimer's disease and senile brains: an immunofluorescence study. Riv Patol Nerv Ment 1983;104:75-87.
65. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-1145.
66. Guo Z, Viitanen M, Fratiglioni L, Winblad B. Low blood pressure and dementia in elderly people: the Kungsholmen project. Br Med J 1996; 312:805-808.
67. Farmer ME, Kittner SJ, Abbott RD, Wolz MM, Wolf PA, White LR. Longitudinally measured blood pressure, antihypertensive medication use, and cognitive performance: the Framingham Study. J Clin Epidemiol 1990;43:475-480.
68. Scherr PA, Hebert LE, Smith LA, Evans DA. Relation of blood pressure to cognitive function in the elderly. Am J Epidemiol 1991;134:1303-1315.
69. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet 1998;352:1347-1351.
70. Di Bari M, Pahor M, Franse LV, et al. Dementia and disability outcomes in large hypertension trials: lessons learned from the Systolic Hypertension in the Elderly Program (SHEP) trial. Am J Epidemiol 2001;153:72-78.
71. Breteler MM, Claus JJ, Grobbee DE, Hofman A. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. Br Med J 1994;308:1604-1608.
72. Wang CH, Zhou X. [Meta-analysis for relationship between apoE gene polymorphism and coronary heart disease], Zhonghua Yu Fang Yi Xue Za Zhi 2003;37:368-370.
73. Treves TA, Bornstein NM, Chapman J, et al. APOE-epsilon 4 in patients with Alzheimer disease and vascular dementia. Alzheimer Dis 1996;10:189-191.
74. Breteler MM. Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann NY Acad Sci 2000;903:457-465.
75. Biessels GJ. Cerebral complications of diabetes: clinical findings and pathogenic mechanisms. Neth J Med 1999;54:34-45.
76. Schwartz MW, Sipols A, Kahn SE, et al. Kinetics and specificity of insulin uptake from plasma into cerebrospinal fluid. Am J Physiol 1990;259:E378-E3S3.
77. Banks WA, Jaspan JB, Kastin AJ. Selective physiological transport of insulin across blood-brain barrier: novel demonstration by species specific radioimmunoassay. Peptides 1997;28:1257-1262.
78. Banks WA, Kastin AJ. Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin. Peptides 1998; 19:883-889.
79. Banks WA, Jaspan JB, Huang W, Kastin AJ. Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. Peptides 1997;18:1423-1429.
80. Park CR. Cognitive effects of insulin in the central nervous system. Neurosci Biobehav Rev 2001;25:311-323.
81. Small SA. The longitudinal axis of the hippocampal formation: its anatomy, circuitry, and role in cognitive function. Rev Neurosci 2002;13: 183-194.
82. Vekrellis K, Ye Z, Qiu WQ, et al. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci 2000;20:1657-1665.
83. Qiu WQ, Walsh DM, Ye Z, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 1998;273:32730-32738.
84. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003;100:4162-4167.
85. Watson GS, Peskind ER, Asthana S, et al. Insulin increases CSF A{beta}42 levels in normal older adults. Neurology 2003;60:1899-1903.
86. Peila R. Rodriguez BL, White LR, Launer LJ. Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology 2004;63:228-233.
87. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004;43:1731-1737.
88. Letenneur L, Larrieu S, Barberger-Gateau P. Alcohol and tobacco consumption as risk factors of dementia: a review of epidemiological studies. Biomed Pharmacother 2004;58:95-99.
89. Breteler MM. Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann NY Acad Sci 2000;903:457-465.
90. Genest J, Jr., Cohn JS. Clustering of cardiovascular risk factors: targeting high-risk individuals. Am J Cardiol 1995;76:8A-20A.
91. Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N Engl J Med 1998; 338:506-511.
92. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-524.